Страна: Канада
мова: англійська
Джерело: Health Canada
ESTRADIOL
NOVARTIS PHARMACEUTICALS CANADA INC
G03CA03
ESTRADIOL
8MG
PATCH (EXTENDED RELEASE)
ESTRADIOL 8MG
TRANSDERMAL
8 PATCHES
Prescription
ESTROGENS
Active ingredient group (AIG) number: 0106457012; AHFS:
CANCELLED POST MARKET
2013-01-08
_ _ _ESTRADERM* _ _Page 1 of 42_ PRODUCT MONOGRAPH PR ESTRADERM*25 ESTRADERM*100 (Estradiol-17ß) Transdermal Therapeutic System 25, and 100 µg/24 hours of estradiol Estrogen * ESTRADERM is a registered trademark NOVARTIS PHARMACEUTICALS CANADA INC. Dorval, Québec, H9S 1A9 Control # 147762 Date of Revision: August 24, 2011 _ _ _ _ _ESTRADERM* _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS..................................................................................................12 DRUG INTERACTIONS ..................................................................................................16 DOSAGE AND ADMINISTRATION..............................................................................18 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 SPECIAL HANDLING INSTRUCTIONS .......................................................................24 PART II: SCIENTIFIC INFORMATION ...............................................................................26 PHARMACEUTICAL INFORMATION..........................................................................26 CLINICAL TRIALS..........................................................................................................26 DETAILED PHARMACOLOGY.....................................................................................29 REFERENCES ..................................................................................................................30 PAR Прочитайте повний документ